Artificial intelligence (AI) and machine learning (ML) have potential to revolutionise cell and gene therapy (CGT), from patient recruitment to supply chain optimisation. Up to 90% of AI/ML models do not make it into production due to challenges in data handling and regulatory hurdles. CGT developers looking to adopt AI must ensure they are aware of these issues and address challenges relating to data availability, limitations in data access, algorithm validation and security.
From a Teams Call to a Ransomware Threat: Matanbuchus 3.0 MaaS Levels Up – Morphisec
From a Teams Call to a Ransomware Threat: Matanbuchus 3.0 MaaS Levels Up Morphisec
